Third Harmonic Bio, Inc.

thirdharmonicbio.com

No Longer Reporting

The company has not filed an annual or quarterly report since its Q1 FY2025 10-Q, filed May 8, 2025. Its latest SEC filing is a SCHEDULE 13G/A from Nov 14, 2025.

The sections below describe the company as of the FY2024 annual report.

What Did They Do?

Develops an oral drug candidate targeting mast cells, initially for chronic spontaneous urticaria and potentially other skin, respiratory and gastrointestinal inflammatory diseases.

How Did They Make Money?

No revenue was reported.

How Were They Changing?

Since the FY2024 annual report

Latest quarter: Q1 FY2025, the three months to Mar 31, 2025

Net income: ▲ +102% (Loss); vs −$7.9M in Q1 FY2024

Jul 31, 2025 Company dissolved and voluntarily delisted its common stock The certificate of dissolution took effect, and Nasdaq trading was suspended.
Jul 21, 2025 Board approved a $5.35-per-share liquidation distribution The CEO was expected to cease serving at a later date.
Apr 14, 2025 Board approved liquidation and dissolution plan The plan was subject to stockholder approval and included a sale of assets, including THB335.